Merck says study shows COVID-19 drug causes quick reduction in virus
(Reuters) - U.S. drug maker Merck & Co Inc said on Saturday that the experimental antiviral drug molnupiravir it is developing with Ridgeback Bio had a faster reduction in infectious disease in its Phase 2a study in participants with early COVID-19 Virus showed.
"The secondary objective results of this study of faster decreases in the infectious virus in individuals with early COVID-19 treated with molnupiravir are encouraging," said William Fischer, associate professor of medicine at the University of North Carolina Medical School Declaration of the company.
The antiviral is currently being tested in a phase 2/3 study, which is expected to be completed in May.
Merck decided to focus on therapeutics after its two COVID-19 vaccines failed to produce the desired immune responses and canceled the program in January.
(Reporting by Ann Maria Shibu in Bengaluru; editing by Christian Schmollinger)
Mention your own website in this post for Advertisement
Antibody cocktail ‘rapidly’ prevents and treats COVID, study finds. Here’s how
Couple Goes Viral When Fiancé Proposes with 5 Different Engagement Rings
'Misleading' for Biden to claim Republicans aren't interested in infrastructure of future: West Virginia senator
Newsmax’s Greg Kelly Called Out for Bashing US Army Lieutenant Pepper Sprayed by Cops
Police: Beaten boy drops from window to escape abusive dad
Minnesota cop shouted 'Taser!' but fired gun